WASHINGTON–(BUSINESS WIRE)– #BRIDGECoalition–The BRIDGE Coalition released a new research paper, authored by Huron, examining the impact of digital learning solutions in higher education.
Month: September 2026
Groupama announces its Half Year Financial Report for 2026 is now available on its website and has been filed with the French stock exchange regulatory authority, l’Autorité des Marchés Financiers.
This document includes the half year 2026 combined financial statements, the half year activity report, the declaration by the person responsible for the Half Year Financial Report as well as the statutory auditors’ review on the half year financial information.
The Half Year Financial Report can be viewed in French on Groupama’s website (www.groupama.com), under the « Analyst / Results » section. The English version will be available on 28 September 2026.
Attachment
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform
WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults1.
With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a pre-cancerous skin condition, actinic keratosis (AK), and a skin cancer. The sBCC indication expands the addressable market for Ameluz and strengthens its position in medical dermatology. This label expansion also furthers Biofrontera’s strategy of broadening the clinical utility of its Red-Light PDT platform. Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, stated: “FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor. This approval reflects years of disciplined investment in the clinical development of Ameluz, and the latest stage in the ongoing expansion of our PDT platform.” He added “We are planning an official launch of the sBCC indication late in the fourth quarter of 2026 through the first quarter of 2027 with our existing commercial organization and installed lamp base. We believe the approval represents a further driver of long-term growth for our existing customers. It also gives new Dermatology practices a reason to purchase a RhodoLED lamp and begin to use Ameluz PDT, expanding our overall installed base.” This new indication utilizes the same topical product (Ameluz) and the same red-light device as the Company’s AK indication, so our existing customers will be able to rapidly adopt this new treatment option.
Basal cell carcinoma (BCC) is the most common skin cancer in the United States, with approximately 3.6 million cases diagnosed annually, according to the Skin Cancer Foundation. Published estimates suggest that the superficial subtype accounts for approximately 15%-20% of BCC cases, or an estimated 540,000 to 720,000 sBCC cases annually in the U.S.2. Superficial BCC lesions can be up to several cm in diameter and are frequently located on the trunk and extremities and often present as multiple lesions, for which non-surgical, tissue-sparing treatment options are limited.
The approval is supported by a multicenter, randomized, double-blind, vehicle-controlled Phase 3 trial in 187 adults with histologically confirmed sBCC. The primary endpoint was a composite of both clinical and histological complete response of a main target lesion 12 weeks after the start of the last PDT cycle. This rigorous target was achieved in 66% of subjects treated with Ameluz PDT (95/145) compared with 5% of subjects treated with placebo-PDT (2/42). Histological clearance of the main target lesion was seen in 76% of Ameluz PDT treated patients versus 19% with Placebo-PDT, and 83% of Ameluz-treated subjects achieved complete clinical clearance of all target lesions compared with 21% for Placebo-PDT. The most common adverse reactions were application-site reactions consistent with the known safety profile of Ameluz PDT.
Dr. M. Shane Chapman, MBA, board certified dermatologist, Professor and Founding Chair, Department of Dermatology, Dartmouth Hitchcock Medical Center and the Dartmouth Geisel School of Medicine, and a key contributor to the Phase 3 study added “For many patients with superficial basal cell carcinoma — those with multiple lesions, lesions in cosmetically sensitive locations, or for whom surgery would not be preferred — treatment options have been limited. This FDA approval for Ameluz® and the RhodoLED gives us a rigorously studied, non-surgical option that we can deliver in our office. As someone who has worked with PDT for many years, I see this as a meaningful expansion in the use of this treatment.”
1 Ameluz Prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208081s040lbl.pdf)
2 Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–47
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with photodynamic therapy (PDT). The Company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, and superficial basal cell carcinoma, and are in development for additional indications. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Investor Contact
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, in this press release, including statements regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words “believe”, “anticipate”, “intend”, “expect”, “target”, “goal”, “estimate”, “plan”, “assume”, “may”, “will”, “predict”, “project”, “would”, “could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should read this press release and any documents referenced herein completely and with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our ability to achieve and sustain profitability; our ability to compete effectively in selling our products; our ability to expand, manage and maintain our direct sales and marketing efforts, including our ability to obtain the financing to develop our marketing strategy, if needed; changes in our relationship with our manufacturing partners and the possible impact of tariffs; our ability to manufacture our products; our ability to adequately protect our intellectual property and operate the business without infringing upon the intellectual property rights of others; our actual financial results may vary significantly from forecasts and from period to period; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; market risks regarding consolidation and group purchasing organizations (“GPOs”) in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third-party payors for our products, or procedures using our products significantly declines; our ability to market, commercialize, achieve market acceptance for and sell our products; the fact that product quality issues or product defects may harm our business; any claims brought against the Company, including but not limited to product liability claims, claims of patent infringement, or claims challenging the validity of our intellectual property; our ability to maintain compliance with The Nasdaq Stock Market, LLC continued listing standards; our ability to comply with the requirements of being a public company; the progress, timing and completion of research, development and preclinical studies and clinical trials for our products; our ability to obtain and maintain the regulatory approvals necessary for the marketing of our products in the United States; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (“SEC”), which can be obtained on the SEC website at www.sec.gov. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.
LONDON–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions
NASHVILLE, Tenn.–(BUSINESS WIRE)–HealthStream (Nasdaq: HSTM), a leading healthcare technology platform company for clinical workforce solutions, today defined the Enterprise Clinical Workforce Platform (ECWP), establishing a new enterprise category for healthcare built on a single, verified record for every clinician. For decades, health systems have standardized on two enterprise systems: the electronic health record (EHR) for the clinical record and enterprise resource planning (ERP) for fi
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 11.09.2026 FDNI.LN IE00BT9PVG14 425,002.00 USD 7,394,146.14 17.398
LINKÖPING, Sweden–(BUSINESS WIRE)– #AMRAMedical–HealthCap Invests in AMRA Medical to meet global demand for precise, scalable advanced muscle and fat imaging in clinical research and healthcare.
Omni One Orders Increase Threefold Following Meta Launch
Company Advances Defense Programs, Enterprise Sales and Acquisition Strategy
AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today provided an update on the strength of its business and progress across its consumer, defense, and enterprise markets, as well as its acquisition strategy.
The number of Omni One orders is up approximately 3X quarter-to-date compared to the same period last year, following the June launch of Omni One for Quest in collaboration with Meta. The acceleration builds on the momentum reported in Virtuix’s first fiscal quarter, when Omni One orders increased 72% year-over-year. The Company believes its integration with the Meta Quest ecosystem significantly expands Omni One’s addressable market and provides a strong foundation for continued consumer growth.
“We continue to see strong momentum across our core markets, with several key catalysts on the horizon,” said Jan Goetgeluk, Founder, Chairman and CEO of Virtuix. “Consumer demand has accelerated significantly following our Meta launch, our defense programs are progressing toward larger opportunities, and Omni One Enterprise is gaining traction across robotics, healthcare, and research. At the same time, we are advancing a potential strategic acquisition that we believe could meaningfully accelerate our revenues and expansion in the defense market.”
Defense Programs Progress Toward Larger Contract Opportunities
Virtuix continues to advance multiple programs with the U.S. Department of Defense. During the current quarter, the Company received its first contract revenue from the U.S. Air Force under its AFWERX Small Business Innovation Research (“SBIR”) Phase I award for Virtuix’s Virtual Terrain Walk (“VTW”) platform. Virtuix expects to complete Phase I this month and intends to submit a proposal for Phase II with support from several U.S. Air Force squadrons and departments. Phase II awards can provide up to approximately $2 million in additional funding and would enable the Company to further deploy its VTW technology for military mission-planning applications.
Virtuix is also showcasing its Counter-Unmanned Aircraft System (C-UAS) Personnel Trainer this week at the Maneuver Warfighter Conference, where U.S. Army and Joint leaders gather to examine current and future requirements of the maneuver force. Developed in collaboration with LeadTech and integrating Omni One, the system enables warfighters to physically maneuver through realistic virtual environments while training to detect and defeat hostile drones.
In addition, Virtuix is advancing its four-person Infantry Fireteam Trainer for the U.S. Marine Corps, with installation at Quantico, Virginia expected later this year. These initiatives form part of Virtuix’s strategy to progress from initial development programs and system deployments toward larger, multi-unit defense contracts.
Virtuix’s defense footprint now includes programs, sales, and collaborations across all four major branches of the U.S. military. Recent milestones include the Air Force SBIR award; appointment as lead systems integrator for the Marine Corps Infantry Fireteam Trainer; entry into counter-drone training; deployments with the U.S. Navy, U.S. Air Force Academy, U.S. Military Academy at West Point, Air National Guard, and Yokota Air Base in Japan; and a cooperative research and development agreement with the U.S. Navy.
Acquisition Strategy Could Accelerate Defense Expansion
Virtuix continues to actively pursue strategic acquisitions in the defense sector and is in advanced negotiations regarding a potential transaction with a target whose annual revenues are near the upper end of the Company’s previously announced target range of $10 million to $50 million, at a valuation and financing structure that, if completed, the Company believes could create significant value for Virtuix shareholders.
Beyond the potential addition of substantial revenue, Virtuix believes a strategic defense acquisition could provide significant benefits through established contract vehicles, past performance, customer relationships, and sales channels across the U.S. Department of Defense. These capabilities could help accelerate Virtuix’s ability to pursue larger contracts for its existing defense technologies, including Virtual Terrain Walk and counter-UAS applications.
The potential transaction remains subject to negotiation, due diligence, definitive agreements, financing, and customary closing conditions, and there can be no assurance that a transaction will be completed.
Enterprise Demand Grows with Follow-On Robotics Sales
Virtuix is also experiencing growing demand for Omni One Enterprise, its commercial platform for industrial training, healthcare, research, AI, robotics and other professional applications. During this quarter, Tesla, Inc. placed repeat Omni One Enterprise orders for use in its Optimus humanoid robot program. Figure AI, another company developing humanoid robots, also purchased Omni One Enterprise, further validating Omni One’s potential role in the rapidly developing embodied-AI and humanoid-robotics markets.
Omni One Enterprise has also been gaining traction in the fields of industrial training, healthcare, and research, with multiple systems sold this quarter to NASA, KBR, Sirica Therapeutics, and various research institutions. Virtuix believes these emerging applications represent an additional, high-margin growth market for its technology beyond its established consumer gaming and defense businesses.
The Company believes the combination of accelerating consumer demand, progression toward larger defense contracts, expanding enterprise adoption, and a potential strategic acquisition positions Virtuix to pursue multiple growth opportunities over the coming quarters.
About Virtuix
Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.
Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectations for continued consumer growth following the Meta integration; the timing, completion, funding, or scope of defense programs, including the AFWERX SBIR Phase II proposal and the Infantry Fireteam Trainer installation; the Company’s ability to progress from initial development programs toward larger defense contracts; the Company’s sales and expansion plans; plans to pursue and complete strategic acquisitions, including the potential transaction currently under negotiation; potential impacts of any acquisition on future revenues, operations, or shareholder value; the Company’s competitive position in the defense training market; and the potential for enterprise applications to represent an additional growth market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to: the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business and realize anticipated synergies or benefits; risks related to government contracting, including contract cancellations, modifications, delays, or funding changes; uncertainties regarding continued consumer demand and market acceptance of the Company’s products; competition in the VR, gaming, defense, and enterprise markets; dependence on third-party relationships, including the Meta partnership; the uncertainties related to general market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com
Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us
KNOXVILLE, Tenn., Sept. 14, 2026 (GLOBE NEWSWIRE) — SafeSpace Global Corporation (OTCID: SSGC) (“SafeSpace Global” or the “Company”), a publicly traded, applied multimodal AI-powered physical safety and security technology company, today announced the completion and successful installation of its integrated school-safety solution in its first K-12 campus in Connecticut.
The deployment uses SafeSpace Global’s camera-agnostic, applied multimodal AI platform to support facial-recognition and weapons-detection applications as part of the school’s broader campus-safety initiative. To protect the privacy and safety of students and staff, the name and specific location of the participating school are not being disclosed.
The installation advances the Company’s mission to help protect lives by supporting earlier threat detection and faster, more informed emergency response.
How the Integrated Solution Works
SafeSpace Global’s integrated solution is designed around a critical principle: identifying a potential threat early, detecting it quickly and providing actionable information to the appropriate personnel can help improve emergency-response times.
The solution operates through four connected steps:
- Identification: SafeSpace Global’s visual AI monitors configured camera feeds to identify person, places, or things.
- Detection: When the platform detects a potential threat, it generates an alert that includes available location information.
- Alert- Human verification: A trained human reviewer evaluates the alert to help reduce false-positive escalations and determine whether further action is appropriate.
- Notification and activation: Once a threat is confirmed, the platform can initiate configured incident-response workflows. Depending on the customer’s systems and protocols, these workflows may include notifying designated school personnel, alerting local authorities, initiating lockdown procedures and providing location intelligence to first responders.
Through its strategic integrations, SafeSpace Global delivers an end-to-end capability designed to shorten the time between initial identification, detection, verification and response.
“This first K-12 installation represents an important milestone for SafeSpace Global and demonstrates how our technology can be deployed within a school’s existing security infrastructure,” said Scott M. Boruff, Founder and Chief Executive Officer of SafeSpace Global Corporation. “Our objective is straightforward: help schools identify potential threats earlier, verify alerts quickly and provide actionable information to the people responsible for responding. We believe bringing these capabilities together can give administrators and first responders more time to act when seconds matter.”
What SafeSpace Global Does
SafeSpace Global provides AI-powered physical-security technology designed to help make everyday environments safer. Its visual AI integrates with a facility’s existing camera infrastructure to identify potential weapons and other designated threats, present alerts for rapid human verification and transmit verified incidents to integrated response platforms.
SafeSpace Global serves multiple sectors, including K-12 education, senior living, addiction-treatment facilities, correctional facilities and faith-based organizations. Its solutions focus on proactive threat identification and providing organizations with actionable information before an incident escalates.
About SafeSpace Global Corporation
SafeSpace Global Corporation (OTCID: SSGC) is a publicly traded technology company providing proprietary, applied multimodal, AI-powered physical safety solutions in its mission to help save lives. Headquartered in Knoxville, Tennessee, the Company has its Tennessee AI Center of Excellence and regional office in Nashville, Tennessee. Learn more at www.SafeSpaceGlobal.ai.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. SafeSpace Global undertakes no obligation to update or revise any forward-looking statements except as required by applicable law. Investors are cautioned not to place undue reliance on these forward-looking statements.
Investor Relations:
Michael Hrynuik
SafeSpace Global Corporation
michael.hrynuik@safespaceglobal.ai
917-885-1174
Media Contact:
Nicole Beal
SafeSpace Global Corporation
marketing@safespaceglobal.ai
Bagsværd, Denmark, 14 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 07 September, the following transactions have been made:
| Number of B shares |
Average purchase price |
Transaction value, DKK |
|
| Accumulated, last announcement | 17,275,000 | 5,221,774,293 | |
| 7 September 2026 | 210,000 | 297.98 | 62,576,264 |
| 8 September 2026 | 210,000 | 295.53 | 62,062,090 |
| 9 September 2026 | 210,000 | 289.37 | 60,767,699 |
| 10 September 2026 | 210,000 | 288.08 | 60,496,529 |
| 11 September 2026 | 210,000 | 278.62 | 58,509,613 |
| Accumulated under the programme | 18,325,000 | 5,526,186,488 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 11 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 33,084,179 B shares at an average share price of DKK 281.89 per B share equal to a transaction value of DKK 9,326,186,478.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com
|
Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
|
| Novo Nordisk Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com
|
Sina Meyer +45 3079 6656 azey@novonordisk.com
|
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com
|
|
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com
|
Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
|
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com
|
Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
Company announcement No 55 / 2026
Attachments
